MétaCan
Menu
Back to cohort

Abstract 12: Germline BRCA mutations in an unselected cohort of patients with pancreatic adenocarcinoma

2014· article· en· W2006033598 on OpenAlexaffabout
Spring Holter, Ayelet Borgida, Anna Dodd, Steven A. Narod, Mohammad R. Akbari, Malcolm J. Moore, Steven Gallinger

Bibliographic record

VenueCancer Research · 2014
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer Genomics and Diagnostics
Canadian institutionsWomen's College HospitalUniversity Health NetworkMount Sinai Hospital
Fundersnot available
KeywordsMedicinePancreatic cancerFamily historyGermline mutationGermlineOncologyBreast cancerAdenocarcinomaOvarian cancerCancerInternal medicineBRCA mutationGenetic testingGynecologyMutationGeneticsBiology

Abstract

fetched live from OpenAlex

Abstract This is the first prospective study to determine the frequency of BRCA1 and BRCA2 germline mutations in an unselected series of patients with pancreatic adenocarcinoma. Patients with histologically or clinically confirmed pancreatic adenocarcinoma were approached at a single cancer centre to enroll in the IRB-approved Ontario Pancreas Cancer Study. Patients provided informed consent and cancer family history data was obtained. Blood was collected and analyzed by Sanger sequencing and MLPA for germline variants in BRCA1 and BRCA2. All predicted deleterious germline variants were confirmed by a clinical laboratory on an independent blood sample. Pathogenic germline mutations were identified in 12/234 (5%) of unselected incident pancreatic adenocarcinomas. BRCA1 mutations accounted for 1.2% (3/234) and BRCA2 accounted for 3.8% (9/234) cases. For the cohort, average age of pancreatic adenocarcinoma diagnosis was 65 years (27-91) and 46% were female. Previous primary cancer was reported in 24% of cases and 12% were of Ashkenazi Jewish descent. A family history of breast and/or ovarian cancer was reported in 25% of cases; however, of these with a family history, 1/3 did not meet NCCN guidelines to warrant germline BRCA analysis. Pancreatic cancer in another relative was reported in 12% of cases. A personal history of a previous primary cancer diagnosis and a family history of breast and/or ovarian cancer were significantly associated with germline BRCA mutations. Previous studies of BRCA mutations in pancreatic adenocarcinoma have been limited to retrospective case series and incomplete germline analysis. Our study shows that germline BRCA mutations account for a significant proportion of pancreatic adenocarcinoma, regardless of family history of breast and ovarian cancer. Increased identification of patients with germline BRCA mutations and pancreatic adenocarcinoma may allow for tailored chemotherapy through the use of platinum agents or PARP inhibitors. Citation Format: Spring Holter, Ayelet Borgida, Anna Dodd, Steven Narod, Mohammad Akbari, Malcolm Moore, Steven Gallinger. Germline BRCA mutations in an unselected cohort of patients with pancreatic adenocarcinoma. [abstract]. In: Proceedings of the AACR Special Conference: Cancer Susceptibility and Cancer Susceptibility Syndromes; Jan 29-Feb 1, 2014; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(23 Suppl):Abstract nr 12. doi:10.1158/1538-7445.CANSUSC14-12

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.321
Teacher spread0.301 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2014
Admission routes2
Has abstractyes

Explore more

Same venueCancer ResearchSame topicCancer Genomics and DiagnosticsFrench-language works237,207